Home > Boards > US Listed > Biotechs > Biohaven Pharmceuticals (BHVN)

20M trading float! >

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
crudeoil24 Member Profile
Member Level 
Followed By 573
Posts 36,816
Boards Moderated 5
Alias Born 12/12/04
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/17/2019 6:30:16 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/3/2019 7:09:13 AM
Biohaven's Verdiperstat, An Oral Myeloperoxidase Inhibitor, Selected For Platform Trial Collaboration At Massachusetts Genera... PR Newswire (US) - 9/18/2019 7:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/13/2019 4:35:33 PM
Biohaven Advances NOJECTION™ Migraine Platform With Completion Of Enrollment Of Pivotal Phase 2/3 Trial Of Vazegepant, The ... PR Newswire (US) - 9/10/2019 7:30:00 AM
Biohaven Presents Data Demonstrating Reduction In Migraine-Related Disability And Improvement In Patient Reported Outcomes Af... PR Newswire (US) - 9/9/2019 7:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/4/2019 7:25:25 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/21/2019 4:12:20 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 8/19/2019 6:42:33 PM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 8/9/2019 4:44:24 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/9/2019 4:33:12 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/9/2019 4:17:28 PM
Biohaven Pharmaceuticals Reports Second Quarter 2019 Financial Results and Recent Business Developments PR Newswire (US) - 8/9/2019 6:47:00 AM
Biohaven Completes Enrollment In Pivotal Phase 3 Migraine Prevention Trial PR Newswire (US) - 8/7/2019 7:30:00 AM
Biohaven Enrolls First Patient In Phase 3 Clinical Trial Of Verdiperstat, Oral Myeloperoxidase Inhibitor, For The Treatment O... PR Newswire (US) - 7/31/2019 7:30:00 AM
Biohaven Provides Update On Phase 2/3 Alzheimer's Disease Clinical Trial: Over 400 Patients Enrolled PR Newswire (US) - 7/22/2019 7:30:00 AM
Biohaven's Positive Phase 3 Trial of Rimegepant Zydis® Orally Dissolving Tablet for Acute Treatment of Migraine Published in... PR Newswire (US) - 7/15/2019 7:30:00 AM
Biohaven Launches 'Demand More' Campaign At 2019 American Headache Society Annual Scientific Meeting: Highlighting Patient Ne... PR Newswire (US) - 7/11/2019 7:30:00 AM
Biohaven Showcases Positive Data on Rimegepant, Oral CGRP Receptor Antagonist, with 16 Presentations at 2019 American Headach... PR Newswire (US) - 7/11/2019 7:30:00 AM
Biohaven's Rimegepant Positive Phase 3 Trial For Acute Treatment Of Migraine Published In The New England Journal of Medicine PR Newswire (US) - 7/10/2019 5:00:00 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 7/10/2019 4:27:44 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2019 5:37:22 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2019 5:36:11 PM
Biohaven Enrolls First Patient in Phase 2 Clinical Trial of Rimegepant, Oral CGRP Receptor Antagonist, for Treatment Refracto... PR Newswire (US) - 7/1/2019 7:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 7:12:12 AM
crudeoil24 Member Level  Tuesday, 06/19/18 08:22:46 AM
Re: investor86 post# 8
Post # of 12 
20M trading float! >

New York Yankees and Duke Basketball
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist